![](https://www.aptitudehealth.com/wp-content/uploads/2021/08/Cancer-Cell-01-Mobile.jpg)
Insights into Renal Cell Carcinoma (RCC)
Current treatment practice regarding therapy of advanced renal cell carcinoma (RCC), recently introduced and upcoming agents
![](https://www.aptitudehealth.com/wp-content/uploads/2021/02/Daniel-Geynisman-M.D.-Aptitude-Health.jpg)
Faculty Chair
Daniel M. Geynisman, MD
Fox Chase Cancer Center, Philadelphia, PA, USA
REPORT SNAPSHOT
- A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on treatment of advanced RCC was held on December 15, 2020, in a virtual setting
- Disease state and data presentations were developed by Daniel M. Geynisman, MD, a medical expert from Fox Chase Cancer Center, Philadelphia
- Insights on the following therapies were obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprised 11 community oncologists from practices in Pennsylvania, Maryland, Virginia, and the District of Columbia